Cargando…
A strategy for effective latent HIV reactivation using subtherapeutic drug doses
Cell state switches underlie a plethora of biological phenomena and disease treatment strategies. Hence the ability to efficiently switch states in a chosen direction is of central importance in a number of scenarios. Increasing the concentration of an effector that results in a given switch is ofte...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709488/ https://www.ncbi.nlm.nih.gov/pubmed/29192171 http://dx.doi.org/10.1038/s41598-017-00097-9 |
_version_ | 1783282789314985984 |
---|---|
author | Cotterell, James Neely, G. Gregory |
author_facet | Cotterell, James Neely, G. Gregory |
author_sort | Cotterell, James |
collection | PubMed |
description | Cell state switches underlie a plethora of biological phenomena and disease treatment strategies. Hence the ability to efficiently switch states in a chosen direction is of central importance in a number of scenarios. Increasing the concentration of an effector that results in a given switch is often limited by side effects. Approaches are thus increasingly sought to bypass these constraints, increasing the frequency of state switching without increasing the frequency of the side effect. Here, we employ dynamical systems theory to uncover a simple strategy as to how to maximize the probability of reactivating latent Human immunodeficiency virus (HIV) whilst maintaining minimal side effects. We demonstrate that continuous supply of an effector is significantly more likely to result in a switch with minimal side effects than the same effector supplied in temporally discrete doses. Importantly this continual dosage is likely to occur far below the Minimum effective dose at a concentration that has classically been thought subtherapeutic. We therefore suggest that in many interventional settings there exists potential to reduce drug dose much further than has previously been thought possible yet still maintaining efficacy. |
format | Online Article Text |
id | pubmed-5709488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-57094882017-12-06 A strategy for effective latent HIV reactivation using subtherapeutic drug doses Cotterell, James Neely, G. Gregory Sci Rep Article Cell state switches underlie a plethora of biological phenomena and disease treatment strategies. Hence the ability to efficiently switch states in a chosen direction is of central importance in a number of scenarios. Increasing the concentration of an effector that results in a given switch is often limited by side effects. Approaches are thus increasingly sought to bypass these constraints, increasing the frequency of state switching without increasing the frequency of the side effect. Here, we employ dynamical systems theory to uncover a simple strategy as to how to maximize the probability of reactivating latent Human immunodeficiency virus (HIV) whilst maintaining minimal side effects. We demonstrate that continuous supply of an effector is significantly more likely to result in a switch with minimal side effects than the same effector supplied in temporally discrete doses. Importantly this continual dosage is likely to occur far below the Minimum effective dose at a concentration that has classically been thought subtherapeutic. We therefore suggest that in many interventional settings there exists potential to reduce drug dose much further than has previously been thought possible yet still maintaining efficacy. Nature Publishing Group UK 2017-11-30 /pmc/articles/PMC5709488/ /pubmed/29192171 http://dx.doi.org/10.1038/s41598-017-00097-9 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Cotterell, James Neely, G. Gregory A strategy for effective latent HIV reactivation using subtherapeutic drug doses |
title | A strategy for effective latent HIV reactivation using subtherapeutic drug doses |
title_full | A strategy for effective latent HIV reactivation using subtherapeutic drug doses |
title_fullStr | A strategy for effective latent HIV reactivation using subtherapeutic drug doses |
title_full_unstemmed | A strategy for effective latent HIV reactivation using subtherapeutic drug doses |
title_short | A strategy for effective latent HIV reactivation using subtherapeutic drug doses |
title_sort | strategy for effective latent hiv reactivation using subtherapeutic drug doses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709488/ https://www.ncbi.nlm.nih.gov/pubmed/29192171 http://dx.doi.org/10.1038/s41598-017-00097-9 |
work_keys_str_mv | AT cotterelljames astrategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses AT neelyggregory astrategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses AT cotterelljames strategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses AT neelyggregory strategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses |